Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma

/PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA...

Related Keywords

France ,Australia ,Suresnes ,France General ,Switzerland ,Israel ,Brazil ,United Kingdom ,Boston ,Massachusetts ,United States ,Canada ,American ,Susan Pandya ,Nathan Mellor ,Prnewswire Servier ,Claude Bertrand ,National Clinical Practice Guidelines In Oncology ,Servier Group Global ,Meeting Of The Society For Neuro ,Servier Pharmaceuticals ,European Medicines Agency ,Servier Group ,Research Development ,Drug Administration ,Access Program ,National Comprehensive Cancer Network Inc ,European Union ,European Commission ,Committee For Medicinal Products Human ,New Drug Application ,Marketing Authorization Application ,Prescription Drug User Fee Act ,Cancer Metabolism Global Development Oncology ,National Clinical Practice Guidelines ,Executive Vice President ,Chief Scientific Officer ,Hazard Ratio ,Confidence Interval ,American Society ,Clinical Oncology ,New England Journal ,Fast Track Designation ,Breakthrough Therapy Designation ,Medicinal Products ,Human Use ,Marketing Application ,Project Orbis ,Expanded Access Program ,Central Nervous System ,Primary Brain ,Accessed February ,Practice Guidelines ,Brain Cancer Gliomas ,National Comprehensive Cancer Network ,Fast Track ,Breakthrough Therapy ,Accelerated Approval ,Medicines Agency ,